Results 211 to 220 of about 4,145,262 (262)
, 2017 Some of the next articles are maybe not open access.
Related searches:
Related searches:
Optimal therapy in medulloblastoma
Acta Neurochirurgica, 1979Twenty-eight children with medulloblastoma (19 boys and 9 girls) were treated at the Departments of Neurosurgery and Radiotherapy in Essen between 1969 and 1977, and were followed prospectively after surgical treatment and postoperative irradiation. Because different radiation techniques had been used, these patients were divided into two groups, one ...
E B, Bongartz +4 more
openaire +2 more sources
Optimization of MammoSite therapy
International Journal of Radiation Oncology*Biology*Physics, 2004Radiation source anisotropy causes about 10% of a spherically shaped planning target volume surrounding a MammoSite balloon to receive less than the prescribed dose. The principal dose-limiting factor for MammoSite therapy is the dose to the overlying skin. Additional limiting factors potentially include the dose to portions of the heart and lung.
Melvin A, Astrahan +2 more
openaire +2 more sources
Optimal Glucocorticoid Therapy
2010The rhythmic regulation of human physiology and behaviour is controlled by a central endogenous clock located in the suprachiasmatic nucleus. Most tissues have peripheral clocks that oscillate in time with this central clock. How the central time keeper controls peripheral clocks is not established, however there is evidence to suggest that the ...
Miguel, Debono, Richard J, Ross
openaire +2 more sources
Optimizing erythropoietin therapy
Current Opinion in Hematology, 1999Much attention has been focused in recent years on ways of optimizing the use and cost-effectiveness of erythropoietin therapy. The balance of evidence suggests that the subcutaneous route allows lower doses to be used compared with the intravenous route, and dosing should be two to three times weekly.
openaire +2 more sources
Optimal therapy for oesophageal cancer
Cancer Treatment Reviews, 2003Oesophageal carcinoma is one of the commonest cancers in the world and has an increasing incidence in Western civilisation. As the epidemiology of the disease has changed so too has our treatment strategies. The present standard of care is surgery but this is associated with disappointing survival figures.
Gregory D, Leonard +2 more
openaire +2 more sources
Optimizing fluid therapy in shock
Current Opinion in Critical Care, 2019Purpose of review Shock, best defined as acute circulatory failure is classified into four major groups, namely hypovolemic, cardiogenic, obstructive, and distributive (vasodilatory). The purpose of this review is to provide a practical approach to fluid optimization in patients with the four types of shock.
Paul E, Marik, Maxwell, Weinmann
openaire +2 more sources
Urologic Oncology: Seminars and Original Investigations, 2009
Bacillus Calmette-Guerin (BCG) is still the most appropriate primary therapy for high-risk patients and appropriate primary or secondary therapy for patients with intermediate-risk disease. The highest disease-free rates will be found in patients who are BCG naïve, have low tumor burden, are stage Ta or CIS, and those relatively younger (
openaire +2 more sources
Bacillus Calmette-Guerin (BCG) is still the most appropriate primary therapy for high-risk patients and appropriate primary or secondary therapy for patients with intermediate-risk disease. The highest disease-free rates will be found in patients who are BCG naïve, have low tumor burden, are stage Ta or CIS, and those relatively younger (
openaire +2 more sources
Optimal antiretroviral therapy for aging
Sexual Health, 2011The introduction of highly active antiretroviral therapy (HAART) has irrevocably changed the nature of the HIV epidemic in developed countries. Although the use of HAART does not completely restore health in HIV-infected individuals, it has dramatically reduced morbidity and mortality.
Damien V, Cordery, David A, Cooper
openaire +2 more sources
Optimizing initial therapy in DLBCL
Best Practice & Research Clinical Haematology, 2018Diffuse large B-cell lymphoma (DLBCL) is a group of lymphomas comprising heterogeneous molecular and biological subtypes, reflected in a broad range of clinical outcomes. With the standard R-CHOP regimen of cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab administered every 21 days, the treatment failure rate remains ...
Catherine, Thieblemont +3 more
openaire +2 more sources